COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia

Leukemia. 2019 Mar;33(3):805-808. doi: 10.1038/s41375-018-0249-z. Epub 2018 Sep 11.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Bispecific / pharmacokinetics*
  • Antibodies, Bispecific / pharmacology*
  • CD3 Complex / metabolism*
  • CHO Cells
  • Cell Line, Tumor
  • Cricetulus
  • Female
  • HL-60 Cells
  • Humans
  • Immunoglobulin G / metabolism*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred NOD
  • Mice, SCID
  • Sialic Acid Binding Ig-like Lectin 3 / metabolism*

Substances

  • Antibodies, Bispecific
  • CD3 Complex
  • CD33 protein, human
  • Immunoglobulin G
  • Sialic Acid Binding Ig-like Lectin 3